VPAS: Current and future impact of UK voluntary pricing schemes
VPAS: Current and future impact of UK voluntary pricing schemes
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) was introduced with the purpose of keeping NHS expenditure on medicines under control, whilst allowing a fair return for the pharmaceutical industry to enable continued R&D and innovation.
Recent successive hikes in annual VPAS repayment rates and the resulting impact on the profitability of branded medicines have resulted in uproar across the UK pharmaceutical industry and widespread calls for reform.
In this report, we discuss the potential impact of increased government rebates on various stakeholders across the pharmaceutical industry, as well as what the replacement voluntary pricing scheme may look like once implemented at the start of 2024.